Hypothalamic Mechanisms in Cachexia
Hypothalamic Mechanisms in Cachexia
批准号:
8249437
负责人:
Daniel L. Marks
金额:
$31.98万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-06-01 至 2014-03-31
关键词:
AcuteAffectAnimalsAnorexiaArousalBasal metabolic rateCachexiaCellsChronicChronic DiseaseCommunicable DiseasesCytokine SignalingCytotoxic ChemotherapyDataDiseaseEatingFeeding behaviorsFundingFutureGene ExpressionGene TransferGeneticGrowthHomeostasisHypothalamic structureInflammationInterleukinsInterventionKidney FailureLifeMalignant NeoplasmsMalnutritionMediatingMelanocortin 4 ReceptorMetabolicMetabolismMicrogliaModelingMorbidity - disease rateMovementMusNeuronsOperative Surgical ProceduresPathway interactionsPatientsPharmacologic SubstancePharmacotherapyPlayPro-OpiomelanocortinProcessProductionQuality of lifeRegulationRoleSeveritiesSignal TransductionSubfamily lentivirinaeSystemTestingTherapeuticTherapeutic InterventionWorkcomputerized data processingcytokinedesigndrug developmenthypocretinincreased appetiteinsulin sensitivityleukemia inhibitory factorlipid metabolismmeetingsmelanin-concentrating hormonemortalitypreventpublic health relevancereceptorrecombinasereproductiveresponsesuccesswasting
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Cachexia, or disease-associated wasting, is a common occurrence in cancer, renal failure, and infectious disease. This devastating state of malnutrition is brought about by a synergistic combination of a dramatic decrease in appetite and an increase in metabolism of fat and lean body mass. The severity of cachexia in many illnesses is the primary determining factor in both quality of life, and in eventual mortality. Other illness induced morbidities including lethargy and loss of reproductive ability also directly compromise the ability of patients to recover from potentially life-saving or extending interventions, including surgery and cytotoxic chemotherapy, and can diminish the motivational drive to aggressively battle the condition. Although cachexia in chronic disease was described more than two thousand years ago, the central mechanisms underlying this disorder of energy homeostasis is poorly understood. Furthermore, there is currently no effective pharmaceutical treatment. The central melanocortin system plays a critical role in regulating feeding behavior, linear growth, metabolic rate, and insulin sensitivity. We have demonstrated that blockade of signaling through the type 4 melanocortin receptor (MC4-R) by genetic and pharmacologic means prevents many of the features of cachexia that would normally occur during acute inflammation in several models of chronic disease. This has led directly to the development of drugs that dampen or block central melanocortin signaling that are currently being tested as therapeutics for cachexia. This proposal is designed to further elucidate the mechanism whereby inflammation leads to excessive activation of central melanocortin signaling. While the primary cytokine signals producing cachexia during illness have been studied in detail, we have limited understanding of the specific hypothalamic cell groups involved in processing these signals. We have shown that cytokines liberated during the disease process activate pro-opiomelanocortin (POMC) neurons by both direct and indirect mechanisms. We have also shown that cytokines affect the function of MCH and orexin neurons, key players in food intake and arousal, respectively. We hypothesize that inflammation alters the function of these neurons and that this in turn will produces various aspects of the illness response including anorexia, decreased movement, elevated basal metabolic rate, lethargy, and alterations in energy partitioning. We further hypothesize that this cellular mechanism represents a final common pathway for the production of cachexia in a variety of chronic disease states, particularly those in which inflammation is known to play an important role.
PUBLIC HEALTH RELEVANCE: The severity of cachexia in chronic disease is often the primary determining factor in both quality of life, and in eventual mortality. Attempts at drug therapy for cachexia with a variety of agents have met with limited success. Our data argues strongly that the hypothalamic melanocortin system plays a critical role in the transduction of illness-induced cachexia and therefore represents an important target for future therapeutic intervention.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PQ6: Therapeutic approaches for autonomic and neuroendocrine dysfunction in cancer cachexia
-
批准号:10303658
-
项目类别:
-
资助金额:$43.28万
-
财政年份:2021
-
负责人:Daniel L. Marks
-
依托单位:
PQ6: Lipocalin-2 as a therapeutic target for prevention of cancer cachexia
-
批准号:10379260
-
项目类别:
-
资助金额:$38.58万
-
财政年份:2021
-
负责人:Daniel L. Marks
-
依托单位:
PQ6: Lipocalin-2 as a therapeutic target for prevention of cancer cachexia
-
批准号:10152268
-
项目类别:
-
资助金额:$39.37万
-
财政年份:2021
-
负责人:Daniel L. Marks
-
依托单位:
PQ6: Therapeutic approaches for autonomic and neuroendocrine dysfunction in cancer cachexia
-
批准号:10490306
-
项目类别:
-
资助金额:$42.41万
-
财政年份:2021
-
负责人:Daniel L. Marks
-
依托单位:
Exosomes as Endocrine Signaling Molecules in Cancer Cachexia
-
批准号:9906180
-
项目类别:
-
资助金额:$43.98万
-
财政年份:2018
-
负责人:Daniel L. Marks
-
依托单位:
Exosomes as Endocrine Signaling Molecules in Cancer Cachexia
-
批准号:10171402
-
项目类别:
-
资助金额:$43.98万
-
财政年份:2018
-
负责人:Daniel L. Marks
-
依托单位:
Exosomes as Endocrine Signaling Molecules in Cancer Cachexia
-
批准号:10394305
-
项目类别:
-
资助金额:$43.1万
-
财政年份:2018
-
负责人:Daniel L. Marks
-
依托单位:
(PQD6) Hypothalamic Inflammation in the Initiation of Cachexia
-
批准号:8994016
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2014
-
负责人:Daniel L. Marks
-
依托单位:
(PQD6) Hypothalamic Inflammation in the Initiation of Cachexia
-
批准号:8845181
-
项目类别:
-
资助金额:$42.24万
-
财政年份:2014
-
负责人:Daniel L. Marks
-
依托单位:
(PQD6) Hypothalamic Inflammation in the Initiation of Cachexia
-
批准号:8680933
-
项目类别:
-
资助金额:$42.24万
-
财政年份:2014
-
负责人:Daniel L. Marks
-
依托单位:
(PQD6) Hypothalamic Inflammation in the Initiation of Cachexia
-
批准号:9079439
-
项目类别:
-
资助金额:$42.24万
-
财政年份:2014
-
负责人:Daniel L. Marks
-
依托单位:
EVOLUTION OF INSULIN RESISTANCE
-
批准号:7206608
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2005
-
负责人:Daniel L. Marks
-
依托单位:
Hypothalamic Mechanisms in Cachexia
-
批准号:8058687
-
项目类别:
-
资助金额:$31.98万
-
财政年份:2004
-
负责人:Daniel L. Marks
-
依托单位:
Hypothalamic Mechanisms in Cachexia
-
批准号:7885233
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2004
-
负责人:Daniel L. Marks
-
依托单位:
Hypothalamic Mechanisms in Cachexia
-
批准号:7920640
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2004
-
负责人:Daniel L. Marks
-
依托单位:
Hypothalamic Mechanisms in Cachexia
-
批准号:6900231
-
项目类别:
-
资助金额:$24.66万
-
财政年份:2004
-
负责人:Daniel L. Marks
-
依托单位:
Hypothalamic Mechanisms in Cachexia
-
批准号:7235331
-
项目类别:
-
资助金额:$25.06万
-
财政年份:2004
-
负责人:Daniel L. Marks
-
依托单位:
Hypothalamic Mechanisms in Cachexia
-
批准号:8441602
-
项目类别:
-
资助金额:$30.86万
-
财政年份:2004
-
负责人:Daniel L. Marks
-
依托单位:
Hypothalamic Mechanisms in Cachexia
-
批准号:7068044
-
项目类别:
-
资助金额:$25.06万
-
财政年份:2004
-
负责人:Daniel L. Marks
-
依托单位:
Hypothalamic Mechanisms in Cachexia
-
批准号:7429671
-
项目类别:
-
资助金额:$25.3万
-
财政年份:2004
-
负责人:Daniel L. Marks
-
依托单位:
海外基金